Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer.
Choughule A, Sharma R, Trivedi V, Thavamani A, Noronha V, Joshi A, Desai S, Chandrani P, Sundaram P, Utture S, Jambhekar N, Gupta S, Aich J, Prabhash K, Dutt A.
Choughule A, et al. Among authors: trivedi v.
Br J Cancer. 2014 Nov 25;111(11):2203-4. doi: 10.1038/bjc.2014.401. Epub 2014 Aug 12.
Br J Cancer. 2014.
PMID: 25117816
Free PMC article.
No abstract available.